Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.71 |
| ▸ | HTT | P42858 | 3/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.66 |
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | HTR7 | P34969 | 1/20 | 0.61 |
| ▸ | FAAH | O00519 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9988381 | 0.87 | HTR7 (0.66) | ALDH1A1HTTSMN1; SMN2LMNAKMT2A | |
| SCHEMBL6681439 | 0.86 | ALDH1A1 (0.83) | ALDH1A1HTTSMN1; SMN2LMNAKMT2A | |
| SCHEMBL4140482 | 0.85 | MEN1 (0.66) | ALDH1A1HTTKMT2AMEN1SIGMAR1 | |
| SCHEMBL2841801 | 0.85 | ALDH1A1 (0.68) | ALDH1A1HTTSMN1; SMN2LMNAKMT2A | |
| SCHEMBL5247018 | 0.85 | FAAH (0.63) | ALDH1A1HTTSMN1; SMN2LMNAKMT2A | |
| SCHEMBL7369921 | 0.85 | ALDH1A1 (0.73) | ALDH1A1HTTSMN1; SMN2LMNAKMT2A | |
| SCHEMBL544161 | 0.85 | SIGMAR1 (0.68) | ALDH1A1HTTSMN1; SMN2LMNAKMT2A | |
| SCHEMBL10981139 | 0.84 | HTR7 (0.63) | ALDH1A1HTTSMN1; SMN2LMNAKMT2A | |
| SCHEMBL2850013 | 0.84 | ALDH1A1 (0.70) | ALDH1A1HTTSMN1; SMN2LMNAKMT2A | |
| SCHEMBL27791391 | 0.84 | ALDH1A1 (0.70) | ALDH1A1HTTSMN1; SMN2LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025090871-A1 | ELECTROPHILIC PURINE COMPOUNDS FOR MODIFICATION OF PROTEINS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-05-01 | — | — | WO | disclosed |
| US-12030871-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | ORION CORPORATION (FI) | 2024-07-09 | — | — | US | disclosed |
| US-20210347765-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORPORATION | 2021-11-11 | — | — | US | disclosed |
| EP-3558981-B1 | PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORP (FI) | 2021-05-26 | — | — | EP | disclosed |
| US-20200299280-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORP (FI) | 2020-09-24 | — | — | US | disclosed |
| US-10717726-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | ORION CORPORATION (FI) | 2020-07-21 | — | — | US | disclosed |
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-22 | — | — | US | disclosed |
| US-7268140-B2 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AG (DE) | 2007-09-11 | — | — | US | disclosed |
| EP-1727526-A2 | PIPERAZINE UREA DERIVATIVES FOR THE TREATMENT OF ENDOMETRIOSIS | Schering Aktiengesellschaft (DE) | 2006-12-06 | — | — | EP | disclosed |
| US-20060135487-A1 | Piperazine derivatives and their use as anti-inflammatory agents | BAUMAN JOHN G | 2006-06-22 | — | — | US | disclosed |
| WO-1995001343-A1 | PYRIDAZINONE DERIVATIVES WITH PHARMACEUTICAL ACTIVITY | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1995-01-12 | — | — | WO | disclosed |
| US-5280024-A | Antioxidant and vasodilator | ADIR ET COMPAGNIE (FR) | 1994-01-18 | — | — | US | disclosed |
| EP-0564350-A1 | 3',5'-ditertbutyl-4'-hydroxyflavones, method for their preparation and pharmaceutical compositions with an antioxidant and antivasoconstricting activity | ADIR ET COMPAGNIE (FR) | 1993-10-06 | — | — | EP | disclosed |
| EP-0060610-B1 | HEXAHYDRO-TRANS- AND TETRAHYDROPYRIDOINDOLE NEUROLEPTIC AGENTS | PFIZER INC. (US) | 1985-09-04 | — | — | EP | disclosed |
| US-4432978-A | NEUROLEPTIC AGENTS, TRANQUILIZERS | PFIZER INC. (US) | 1984-02-21 | — | — | US | disclosed |
| US-4431649-A | TRANQUILIZERS | PFIZER INC. (US) | 1984-02-14 | — | — | US | disclosed |
| US-4431646-A | TRANQUILIZERS; PSYCHOSIS; NERVOUS SYSTEM DISORDERS | PFIZER INC. (US) | 1984-02-14 | — | — | US | disclosed |
| US-4427679-A | TRANQUILIZERS; PSYCHOLOGICAL DISORDERS | PFIZER INC. (US) | 1984-01-24 | — | — | US | disclosed |
| EP-0060610-A1 | Hexahydro-trans- and tetrahydropyridoindole neuroleptic agents | PFIZER INC. (US) | 1982-09-22 | — | — | EP | disclosed |
| US-4337250-A | NEUROLEPTIC AGENTS | PFIZER INC. (US) | 1982-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10717726-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | CYP11B1, CYP11B2, CYP4A11 | ALDH1A1 133/4885HTT 4876/4885SMN1; SMN2 4744/4885 |
| US-20210347765-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | CYP11B1, CYP11B2, CYP4A11 | ALDH1A1 133/4885HTT 4876/4885SMN1; SMN2 4744/4885 |
| US-20060135487-A1 | Piperazine derivatives and their use as anti-inflammatory agents | IL5, PTGES2, PTGES | ALDH1A1 465/4885HTT 1362/4885SMN1; SMN2 4729/4885 |
| US-12030871-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | CYP11B1, CYP11B2, CYP4A11 | ALDH1A1 133/4885HTT 4876/4885SMN1; SMN2 4744/4885 |
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | ESR2, GPER1, SLC14A1 | ALDH1A1 306/4885HTT 2898/4885SMN1; SMN2 4648/4885 |
| US-20200299280-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | CYP11B1, CYP11B2, CYP4A11 | ALDH1A1 133/4885HTT 4876/4885SMN1; SMN2 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.